Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.
In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.
Scientists at the University of Toronto's Leslie Dan Faculty of Pharmacy have seen remarkable success combining tumor modulating nanoparticles with doxorubicin to enhance chemotherapy response in pre-clinical model breast cancer.
Approximately 10-20 percent of diagnosed breast cancers are found to be triple-negative, meaning the breast cancer cells test negative for estrogen and progesterone receptors as well as HER2 receptors, genes that can play a role in the development of breast cancer.
Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.
Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.
Among a small cohort of patients with HIV-associated Kaposi's sarcoma treated with immune checkpoint inhibitors, more than 65 percent had partial or complete remission.
Recently published results of a phase 2 clinical trial have shown the best outcomes to date for newly diagnosed older Hodgkin lymphoma patients treated with brentuximab vedotin given before and after doxorubicin, vinblastine and dacarbazine chemotherapy, which is the standard of care.
Patients with muscle-invasive bladder cancer have been shown to benefit from chemotherapy prior to surgical removal of the bladder.
Chemists at Hong Kong Baptist University have discovered the use of a metal compound that inhibits the enzyme closely associated with triple-negative breast cancer, one of the most difficult forms of breast cancer to treat.
A joint research team from Russia and the U.K. has demonstrated the possibility of developing a new type of anti-neoplastic drugs based on nanoMIPs, or "plastic antibodies." NanoMIPs are synthetic polymers that can function as antibodies, selectively binding to target proteins on the surface of cancer cells.
The new treatment will serve as both diagnosis and treatment of malignant tumors. This breakthrough in the technologies of cancer diagnosis and treatment was made by an interdisciplinary Russian-German collaboration of chemists, physicists, and biologists from NUST MISIS, Lomonosov Moscow State University, Pirogov Russian National Research Medical University (RNRMU), and the University of Duisburg-Essen (Germany).
Cancer tissue cells are divided into two major groups: cancer cells and cancer stem cells. CSCs are related to cancer progression and dissemination, so it's necessary to eradicate CSCs in order to cure cancer.
Doxorubicin is a chemotherapy drug widely used in ovarian, bladder, lung, thyroid and stomach cancers, but it carries a harmful side effect. The drug causes a dose-dependent heart toxicity that can lead to congestive heart failure.
Pfizer Inc. today announced the European Commission has approved TRAZIMERA, a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Scientists have developed a technique that allows them to measure how well cancer drugs reach their targets inside the body.
A team of researchers from the CNRS and Université Nice Sophia Antipolis has just shown that a small molecule called methiothepin can inhibit the chemotherapy resistance of certain tumors.
Fuyuhiko Tamanoi of Kyoto University's Institute for Integrated Cell-Material Sciences and colleagues in the US succeeded in establishing a versatile, powerful and convenient model to analyze human cancer.
How can we detect cancer and viruses with high sensitivity? Physical chemist Laura Fabris-;an associate professor in the Materials Science and Engineering Department at Rutgers, the State University of New Jersey, and principal investigator of the Fabris NanoBio Group-;is addressing this very question.
A new study showing significantly improved survival rates for patients with stage IV Wilms tumors with lung metastases was recently published in the Journal of Clinical Oncology.
In the wrestling match with cancer, chemoimmunotherapy is the new strong arm, and it is building muscle with a nanodisc disguised as "good cholesterol."
People with tough-to-treat triple negative breast cancer, whose tumors also don't allow for double-strand DNA repair, fare better when treated with a common adjuvant breast cancer chemotherapy combination, according to results from a SWOG clinical trial.